Overview

Body Protection Compound derived from gastric juice protein. Promotes healing of gut, tendons, ligaments, and muscles through enhanced angiogenesis.

Global Regulatory Status

Approval status across major regulatory agencies worldwide.

FDA
United States
Research
TGA
Australia
Not Approved
EMA
European Union
Not Approved
MHRA
United Kingdom
Not Approved
PMDA
Japan
Not Approved
NMPA
China
Not Approved
Note: "Unknown" status indicates that comprehensive regulatory information is not yet available in our database. This does not necessarily mean the peptide is not approved. For critical medical decisions, always verify current regulatory status with the relevant health authority.

Mechanism of Action

Promotes angiogenesis via VEGF pathway, stabilizes gastric mucosa, accelerates wound healing through nitric oxide pathway modulation.

Stability & Storage

Form Storage Conditions Shelf Life
Lyophilised
(Freeze-Dried)		 Store at -20°C to -80°C for long-term storage (6-12 months). Can be stored at 2-8°C for up to 3 months. Protect from light and moisture. 6-12 months
Reconstituted
Solution		 After reconstitution with bacteriostatic water, store at 2-8°C for up to 14-21 days. With sterile water, use within 3-5 days. Do not freeze reconstituted solution. 14-21 days
⚠️ Storage Best Practices
  • Always store in original packaging until ready to use
  • Protect from light, moisture, and temperature fluctuations
  • Never refreeze after thawing
  • Use proper sterile technique when reconstituting
  • Discard if solution becomes cloudy or discolored

Target Information

Target Receptors
No specific receptor identified; modulates growth factor receptors (VEGFR, EGFR), nitric oxide pathways
Target Tissues
  • Gastric mucosa
  • vascular endothelium
  • tendon/ligament connective tissue
  • muscle tissue
  • epithelial tissue
Target Organs
  • Stomach
  • intestines
  • tendons
  • ligaments
  • blood vessels
  • skin
  • liver
  • nervous system

Pharmacokinetics: Half-Life by Administration Route

The biological half-life varies significantly depending on the route of administration. This affects dosing frequency and duration of action.

Administration Route Half-Life Clinical Implications
Subcutaneous (SC) Approximately 4 hours after subcutaneous injection based on preclinical studies. Oral bioavailabilit Slower absorption, sustained release, most common route

Note: Half-life values can vary between individuals based on factors including age, metabolism, kidney/liver function, and co-administered medications.

Molecular Structure

Amino Acid Sequence

2D Chemical Structure

Interactive 2D structure rendered from SMILES notation

3D Molecular Model

3D structure model will be available soon

Structure visualization powered by 3Dmol.js (integration pending)

Peptide Composition & Modifications

Amino Acid Composition

Natural L-Amino Acids
15 residues
Total Length
15 amino acids

Terminus Modifications

N-Terminus (Amino Terminus)
Free NH2 (Glycine)
C-Terminus (Carboxyl Terminus)
Free COOH (Valine)

Terminal modifications can protect against exopeptidase degradation and modulate biological activity.

Nomenclature

Standard Abbreviation
BPC-157
Also Known As
  • Body Protection Compound 157
  • Pentadecapeptide BPC 157
  • PL 14736
  • PL-10

Dosage & Administration

Research doses: 200-1000 mcg daily, SC or oral

⚠️ Medical Supervision Required

This information is for educational purposes only. Dosing should only be determined by a qualified healthcare provider based on individual patient needs and medical history.

Scientific References

References are organized by topic for easy navigation. Click on PubMed links to view the full articles.

Angiogenesis

Sikiric P, et al.
The influence of a novel pentadecapeptide, BPC 157, on NO-system
Journal of Physiology and Pharmacology (1997)

Mechanism of Action

Sikiric P, et al.
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Current Pharmaceutical Design (2011)
PubMed: 21443487 DOI: 10.2174/138161211796196954 Full Text

Tendon & Ligament Healing

Krivic A, et al.
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157
Journal of Physiology and Pharmacology (2006)
PubMed: 17218761 Full Text

Research & Clinical Status

Extensive animal studies. Human clinical trials limited. Not FDA approved.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or medication. The information provided here is based on available scientific literature and may not be complete or up-to-date.